Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia Post author: Post published:March 1, 2026 Post category: Continue ReadingStudy of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma Post author: Post published:March 1, 2026 Post category: Continue ReadingA Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH – SLE/LN) Post author: Post published:March 1, 2026 Post category: Continue ReadingA Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH – SLE/LN)
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma Post author: Post published:March 1, 2026 Post category: Continue ReadingA Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
The American Society of Hematology (ASH) Research Registry: A Multicenter Research Registry of Patients With Hematologic Disease Post author: Post published:March 1, 2026 Post category: Continue ReadingThe American Society of Hematology (ASH) Research Registry: A Multicenter Research Registry of Patients With Hematologic Disease
A Study to Evaluate the Safety of a Delivery Device for Administering LCTOPC1 in Participants With Spinal Cord Injury Post author: Post published:March 1, 2026 Post category: Continue ReadingA Study to Evaluate the Safety of a Delivery Device for Administering LCTOPC1 in Participants With Spinal Cord Injury
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2) Post author: Post published:March 1, 2026 Post category: Continue ReadingA Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults Post author: Post published:March 1, 2026 Post category: Continue ReadingStem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas Post author: Post published:March 1, 2026 Post category: Continue ReadingAutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Autologous Gene Therapy for Artemis-Deficient SCID Post author: Post published:March 1, 2026 Post category: Continue ReadingAutologous Gene Therapy for Artemis-Deficient SCID
